KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Capital Expenditures (2016 - 2023)

Historic Capital Expenditures for Palvella Therapeutics (PVLA) over the last 10 years, with Q4 2023 value amounting to -$13000.0.

  • Palvella Therapeutics' Capital Expenditures fell 1818.18% to -$13000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$13000.0, marking a year-over-year decrease of 10751.45%. This contributed to the annual value of $171000.0 for FY2023, which is 8357.35% down from last year.
  • Palvella Therapeutics' Capital Expenditures amounted to -$13000.0 in Q4 2023, which was down 1818.18% from $69000.0 recorded in Q3 2023.
  • In the past 5 years, Palvella Therapeutics' Capital Expenditures ranged from a high of $1.9 million in Q1 2020 and a low of -$840000.0 during Q3 2020
  • For the 5-year period, Palvella Therapeutics' Capital Expenditures averaged around $367450.0, with its median value being $230500.0 (2019).
  • Within the past 5 years, the most significant YoY rise in Palvella Therapeutics' Capital Expenditures was 149256.2% (2020), while the steepest drop was 46206.9% (2020).
  • Palvella Therapeutics' Capital Expenditures (Quarter) stood at $1.2 million in 2019, then tumbled by 50.85% to $578000.0 in 2020, then plummeted by 40.83% to $342000.0 in 2021, then tumbled by 103.22% to -$11000.0 in 2022, then fell by 18.18% to -$13000.0 in 2023.
  • Its Capital Expenditures stands at -$13000.0 for Q4 2023, versus $69000.0 for Q3 2023 and $67000.0 for Q2 2023.